Effects of leucine-enriched whey protein supplementation on physical function in post-hospitalized older adults participating in 12-Weeks of resistance training program: a randomized controlled trial
In March 2024, the FDA approved the use of Wegovy to reduce the risk of heart attack and stroke in adults with cardiovascular disease (CVD) who were either obese or overweight
Standard Cagrilintide Monotherapy Chart CAGRILINTIDE ESCALATION PROTOCOL Week 1-4: [0.6 mg] Tolerance Assessment Week 5-8: [1.2 mg] Efficacy & Safety Review Week 9+: [2.4 mg] Maintenance Monitoring Theoretical Combination Dosing Chart For cagrilintide dosage with tirzepatide , a theoretical combination chart might look like: COMBINATION PROTOCOL (THEORETICAL) TIRZEPATIDE CAGRILINTIDE Week 1-4: 2.5 mg None Week 5-8: 5.0 mg None Week 9-12: 7.5 mg None Week 13-16: 7.5 mg 0.6 mg Introduction Week 17-20: 10 mg 1.2 mg Week 21+: 12.5 mg 2.4 mg Optimization This staged approach minimizes the risk of overwhelming gastrointestinal side effects while allowing for individualized dose optimization
Active ingredients (per patch)
Mounjaro (tirzepatide) is a GLP-1 and GIP receptor agonist, designed to help regulate blood sugar, reduce appetite, and promote weight loss
Glucagon-like peptide-1 agonists: a practical overview for plastic and reconstructive surgeons
